home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Events -> Meetings and Conferences  

Strategic Implications of Oncology Clinical Trial Design in Early-Phase Studies

  January 24, 2024  
Xtalks, Online

Discover an informative webinar delving into how strategic oncology clinical trial design shapes success in early oncology studies using novel approaches. Trial design in early-phase oncology studies has a critical impact on the success of the study. Novel approaches such as biomarker stratification, adaptive enrichment designs, outcome-adaptive randomization and the integration of real-world data have been developed. In addition, under Project Optimus, dose expansion requires the selection of the most appropriate dose and schedule to be brought into the registrational trial, which also needs to be accomplished via dose-finding studies in early-phase trials.

Attendees will learn insights into the trade-offs between protocol design options and offer insight into developing a trial structure that maximizes the chances of success in later phases of research while minimizing risk.



Join this webinar to explore the intricate world of oncology trial design and gain valuable insights to enhance research approaches.

Keywords: Clinical Trials, Drug Development, Clinical Research, CRO, Oncology, Biomarkers, Clinical Data, Oncology Clinical Trials, Clinical Trial Design, Early-Phase Trials
Organized by: Xtalks
Invited Speakers: Peter Langecker, MD, PhD, Executive Medical Director, Global Oncology, Caidya
Deadline for Abstracts: 2024-02-16
Registration: Free Registration
E-mail: tristan@xtalks.com
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.